Comparative Pharmacology
Head-to-head clinical analysis: CHLOROFAIR versus READYPREP CHG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROFAIR versus READYPREP CHG.
CHLOROFAIR vs READYPREP CHG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Chlorhexidine gluconate disrupts microbial cell membranes, causing leakage of cytoplasmic contents and cell death. Its cationic nature binds to negatively charged bacterial cell walls, providing persistent antimicrobial activity.
125 mg IV every 6 hours for 10 days.
No standard systemic dosing; used as a 4% chlorhexidine gluconate topical antiseptic solution applied once daily to entire body for preoperative skin preparation or for chlorhexidine bathing in infection prevention protocols.
None Documented
None Documented
4.5 hours (prolonged to 10–12 hours in renal impairment)
60 minutes (terminal) in patients with normal renal function; prolonged in renal impairment.
Renal: 70% unchanged; hepatic metabolism: 25% conjugated; fecal: 5%
Renal: ~100% unchanged via glomerular filtration. No biliary or fecal elimination.
Category C
Category C
Antiseptic
Antiseptic